{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+First&page=3",
    "query": {
      "intervention": "Placebo First",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 3253,
    "total_pages": 326,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+First&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+First&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T06:24:17.117Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00624468",
      "title": "Atacicept in Subjects With Optic Neuritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Optic Neuritis"
      ],
      "interventions": [
        {
          "name": "Atacicept",
          "type": "DRUG"
        },
        {
          "name": "Placebo matched to atacicept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 34,
      "start_date": "2008-06",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2016-02-17",
      "last_synced_at": "2026-10-18T06:24:17.117Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Aurora, Colorado • Fairfield, Connecticut + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "East Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00624468"
    },
    {
      "nct_id": "NCT00549640",
      "title": "Testing Methylphenidate for Smoking Abstinence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Smoking"
      ],
      "interventions": [
        {
          "name": "Methylphenidate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2008-01",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2011-04-19",
      "last_synced_at": "2026-10-18T06:24:17.117Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00549640"
    },
    {
      "nct_id": "NCT01885260",
      "title": "Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "ISIS-GCGRRx - Dose Level 1",
          "type": "DRUG"
        },
        {
          "name": "ISIS-GCGRRx - Dose Level 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 77,
      "start_date": "2013-07",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2016-07-04",
      "last_synced_at": "2026-10-18T06:24:17.117Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Anaheim, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01885260"
    },
    {
      "nct_id": "NCT01779024",
      "title": "Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "fMRI",
        "Alcohol Drinking",
        "Alcoholism"
      ],
      "interventions": [
        {
          "name": "Ghrelin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "fMRI",
          "type": "PROCEDURE"
        },
        {
          "name": "Alcohol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 17,
      "start_date": "2012-12-13",
      "completion_date": "2017-06-01",
      "has_results": true,
      "last_update_posted_date": "2018-08-03",
      "last_synced_at": "2026-10-18T06:24:17.117Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01779024"
    },
    {
      "nct_id": "NCT00594568",
      "title": "Effect of LY450139 on the Long Term Progression of Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "LY450139",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 1537,
      "start_date": "2008-03",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2015-03-17",
      "last_synced_at": "2026-10-18T06:24:17.117Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00594568"
    },
    {
      "nct_id": "NCT01186991",
      "title": "Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Onartuzumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab Placebo",
          "type": "DRUG"
        },
        {
          "name": "Onartuzumab Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 185,
      "start_date": "2011-03",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2017-01-20",
      "last_synced_at": "2026-10-18T06:24:17.117Z",
      "location_count": 23,
      "location_summary": "Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01186991"
    },
    {
      "nct_id": "NCT06699680",
      "title": "Phase 1 Study of PRX019 in Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants Study"
      ],
      "interventions": [
        {
          "name": "PRX019",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prothena Biosciences Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2024-11-08",
      "completion_date": "2026-01-16",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-10-18T06:24:17.117Z",
      "location_count": 1,
      "location_summary": "Los Alamitos, California",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06699680"
    },
    {
      "nct_id": "NCT04592380",
      "title": "Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyspnea",
        "Hypertension",
        "Acute Heart Failure"
      ],
      "interventions": [
        {
          "name": "Stage 1: Clevidipine (double-blinded)",
          "type": "DRUG"
        },
        {
          "name": "Stage 1: Placebo (double-blinded)",
          "type": "DRUG"
        },
        {
          "name": "Stage 2: Clevidipine (open-label)",
          "type": "DRUG"
        },
        {
          "name": "Stage 2: Standard of Care (open-label)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Medicines Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-08",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-10-18T06:24:17.117Z",
      "location_count": 9,
      "location_summary": "Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04592380"
    },
    {
      "nct_id": "NCT07699380",
      "title": "METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes (T1D)",
        "Metabolic Diseases",
        "Glucose Metabolism Disorders",
        "Endocrine System Diseases",
        "Autoimmune Diseases",
        "Immune System Diseases",
        "Diabetes Melletus, Type 1",
        "Nutritional and Metabolic Diseases",
        "Combination Therapy"
      ],
      "interventions": [
        {
          "name": "AMX0035",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-09",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-18T06:24:17.117Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07699380"
    },
    {
      "nct_id": "NCT03229174",
      "title": "Brain Perfusion & Oxygenation in Parkinson's Disease With NOH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson Disease",
        "Neurogenic Orthostatic Hypotension"
      ],
      "interventions": [
        {
          "name": "Droxidopa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "William Ondo, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 17,
      "start_date": "2018-08-23",
      "completion_date": "2022-02-02",
      "has_results": false,
      "last_update_posted_date": "2022-09-06",
      "last_synced_at": "2026-10-18T06:24:17.117Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03229174"
    }
  ]
}